Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.

2023 Annual Meeting →

Stock quote is delayed by 15 minutes
NASDAQANIK
Woman throwing punch at punching bag.

Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.

2023 Annual Meeting →

Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics

(As of December 31, 2022)

  • $156M

    FY’22 Revenue

    6% YtY Growth

  • 11%

    Revenue CAGR

    FY’19 – FY’22

  • #1

    U.S. Market Share

    OA Pain Management

  • $86M

    Cash balance
    with no debt

Recent News
May 30, 2023

Hyalofast – a single-stage, off-the-shelf, resorbable, hyaluronic acid scaffold for cartilage repair is marketed in over 35 countries outside the U.S. where it has been clinically demonstrated...

May 9, 2023

BEDFORD, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results...

Apr 19, 2023

BEDFORD, Mass., April 19, 2023 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue...

All Press Releases

Featured Event
Tuesday, May 9, 2023
5:00pm - 6:00pm EDT

See All Events

Current Investor Presentation
Investor Contacts

Primary IR Contact

  • Mark Namaroff

    Vice President, Investor Relations, ESG, and Corporate Communications

    Anika Therapeutics, Inc.

    Phone: (781) 457-9287

    Email: investorrelations@anika.com

  • Transfer Agent

    American Stock Transfer & Trust Co.

    59 Maiden Lane

    New York, NY 10038

    Phone: (718) 921-8261

Want Alerts? Sign up for alerts and never miss an Investor update!

Subscribe

To Top